208 related articles for article (PubMed ID: 31115106)
1. Comparison of the predictive value among inflammation-based scoring systems for bleomycin pulmonary toxicity in patients with germ cell tumors.
Maruyama Y; Sadahira T; Araki M; Mitsui Y; Wada K; Edamura K; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Int J Urol; 2019 Aug; 26(8):813-819. PubMed ID: 31115106
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inflammation-based prognostic scores as predictors of survival outcomes in patients with germ cell tumors.
Yoshinaga K; Sadahira T; Maruyama Y; Mitsui Y; Iwata T; Wada K; Araki M; Watanabe T; Nasu Y
Investig Clin Urol; 2021 Jan; 62(1):47-55. PubMed ID: 33314803
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of bleomycin pulmonary toxicity on the outcomes of patients with germ cell tumors.
Maruyama Y; Sadahira T; Mitsui Y; Araki M; Wada K; Tanimoto R; Kobayashi Y; Watanabe M; Watanabe T; Nasu Y
Med Oncol; 2018 Apr; 35(6):80. PubMed ID: 29700638
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3).
Shamash J; Sarker SJ; Huddart R; Harland S; Joffe JK; Mazhar D; Birtle A; White J; Chowdhury K; Wilson P; Marshall MR; Vinnicombe S
Ann Oncol; 2017 Jun; 28(6):1333-1338. PubMed ID: 28327896
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin.
Lauritsen J; Kier MG; Bandak M; Mortensen MS; Thomsen FB; Mortensen J; Daugaard G
J Clin Oncol; 2016 May; 34(13):1492-9. PubMed ID: 26903578
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors.
Ozols RF; Ihde DC; Linehan WM; Jacob J; Ostchega Y; Young RC
J Clin Oncol; 1988 Jun; 6(6):1031-40. PubMed ID: 2453619
[TBL] [Abstract][Full Text] [Related]
7. Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center.
Aurilio G; Verri E; Frassoni S; Bagnardi V; Cossu Rocca M; Cullurà D; Milani M; Mascia R; Curigliano G; Orsi F; Jereczek-Fossa BA; Musi G; Omodeo Salè E; De Cobelli O; Nolè F
Am J Clin Oncol; 2020 Jun; 43(6):381-387. PubMed ID: 32079853
[TBL] [Abstract][Full Text] [Related]
8. Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers.
den Hollander MW; Westerink ND; Lubberts S; Bongaerts AH; Wolf RF; Altena R; Nuver J; Oosting SF; de Vries EG; Walenkamp AM; Meijer C; Gietema JA
Oncologist; 2016 Aug; 21(8):995-1001. PubMed ID: 27328932
[TBL] [Abstract][Full Text] [Related]
9. Frequency and risk factors of bleomycin-induced pulmonary toxicity in South Indian patients with germ-cell tumors.
Thakkar DN; Ramasamy K; Adithan S; Selvarajan S; Dubashi B
J Cancer Res Ther; 2021; 17(2):443-449. PubMed ID: 34121690
[TBL] [Abstract][Full Text] [Related]
10. High-risk germ cell tumors in men. High response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide.
Blayney DW; Goldberg DA; Leong LA; Margolin KA; Burke JS; Doroshow JH
Cancer; 1993 Apr; 71(7):2351-7. PubMed ID: 7680946
[TBL] [Abstract][Full Text] [Related]
11. The effect of pulmonary function testing on bleomycin dosing in germ cell tumours.
Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P;
Intern Med J; 2016 Aug; 46(8):893-8. PubMed ID: 27305276
[TBL] [Abstract][Full Text] [Related]
12. Sequential trials of cisplatin, vinblastine, and bleomycin and etoposide and cisplatin in disseminated nonseminomatous germ cell tumors of the testis with a good prognosis at a single institution.
Germá JR; Sagarra AF; Izquierdo MA; Seguí MA
Cancer; 1993 Feb; 71(3):796-803. PubMed ID: 7679314
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
14. Bleomycin lung toxicity detected by technetium-99m diethylene triamine penta-acetic acid aerosol scintigraphy.
Ugur O; Caner B; Balbay MD; Ozen HA; Remzi D; Ulutuncel N; Bekdik C
Eur J Nucl Med; 1993 Feb; 20(2):114-8. PubMed ID: 7679991
[TBL] [Abstract][Full Text] [Related]
15. Ambulatory infusion of bleomycin in patients receiving chemotherapy for germ cell tumors.
Green JA; Hammond P; Watkin SW
Sel Cancer Ther; 1989; 5(2):93-5. PubMed ID: 2475900
[No Abstract] [Full Text] [Related]
16. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.
Bosl GJ; Geller NL; Bajorin D; Leitner SP; Yagoda A; Golbey RB; Scher H; Vogelzang NJ; Auman J; Carey R
J Clin Oncol; 1988 Aug; 6(8):1231-8. PubMed ID: 2457657
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary alterations during BEP? Always be aware of BIP.
Sleijfer S
Onkologie; 2007 Jun; 30(6):291-2. PubMed ID: 17551251
[No Abstract] [Full Text] [Related]
18. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study.
Curigliano G; Spitaleri G; Magni E; Lorizzo K; De Cobelli O; Locatelli M; Fumagalli L; Adamoli L; Cossu Rocca M; Verri E; De Pas T; Jereczek-Fossa B; Martinelli G; Goldhirsch A; Nolè F
J Chemother; 2009 Dec; 21(6):687-92. PubMed ID: 20071294
[TBL] [Abstract][Full Text] [Related]
19. Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older.
Thomsen FB; Bandak M; Thomsen MF; Lauritsen J; Christensen IJ; Daugaard G
Cancer; 2014 Jan; 120(1):43-51. PubMed ID: 24108413
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
